OBJECTIVES: Diabetes-related minor hypoglycemic episodes (MHEs) have been found to be significantly related to decreased treatment satisfaction. Unfortunately little is known regarding the impact of MHEs on work productivity and costs for people who work. METHODS: A US web-based survey of persons with diabetes was conducted. RESULTS: 6,756 persons with diabetes were surveyed. Of these 830 had at least one MHE in the past month, of whom 411 indicated working for pay, which is the population used for this analysis. Of the 411, 200 (48.7%) respondents had type 1 and 211 (51.3%) had type 2 diabetes. 290 (70.6%) were taking insulin and 121 (29.4%) used only oral hypoglycemic agents. The mean age was 49.5 13.2, 64.0% were females and average duration of diabetes was 15.8 12.7 years. 385 (94%) reported MHEs, either at work or during sleep which affected their work, in the past year. For their latest MHE at work, the average amount of time respondents reported not functioning at their usual work productivity level (presenteeism) was 9.1 hours. 34 subjects reported 1.0 days of absence from work after a MHE at the work place (e.g. leaving early or missing meetings). Additionally, 31 respondents had MHE during the night which resulted in 1.7 days of absence the following days. On average, these respondents used 6.9 extra blood sugar monitoring tests per MHE and $66.25 out-of-pocket was spent on foods, glucose products, changes in transportation, etc. in the past month due to MHEs. CONCLUSIONS: It appears that lost productivity (presenteeism and absenteeism) and the costs of MHEs have been underestimated and should be considered an important part of diabetes management. Treatments which reduce MHEs would increase work productivity and decrease cost of care. OBJECTIVES: As in most countries, Diabetes Mellitus is a disease causing significant burden to Turkey. The treatments and their benefits affect not only the patient, but their friends, families and other relationships as well. Therefore, feedback regarding the quality of life of a Diabetes Mellitus patient is meaningful. The aim of this study was to determine the reliability and validity of the Diabetes Health Profile-1 (DHP-1) for Turkish Diabetic patients. METHODS: The scale, which was translated into Turkish from English, again translated back into English by 2 independent translators, was applied to 45 diabetic patients for pre-test. After assessment of the results, the questionnaire was applied to 60 diabetic patients. Cronbach's Alfa was used to assess reliability and factor analysis to assess dimensionality. The EuroQol-5D was used for concurrent validity. RESULTS: The internal consistency coefficient (Cronbach's alpha) of DHP-1was 0.86. Factor analysis of the scale revealed that it was composed of five factors with Eigenvalues 1, accounting for 74.4% of the total variance. All items of the Turkish DHP had a factor load ranging from 0.578 to 0.838. CONCLUSIONS: The DHP-1 has good validity and reliability for Turkish Diabetic patients.
PDB52 PATIENT TREATMENT SATISFACTION OF TYPE 2 DIABETIC PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN USING INSULINS GLARGINE OR DETEMIR AS BASAL INSULIN: RESULTS FROM THE LIVE-COM STUDY
Moock J 1 , Hessel F 2 , Kohlmann T 1 1 University of Greifswald, Greifswald, Germany, 2 Sanofi-Aventis, Berlin, Germany OBJECTIVES: Although basal insulins glargine (GLA) or detemir (DET) appear to have similar clinical efficacy for treatment of type 2 diabetes (T2D), there are several differences between these two regimens that could affect outcomes from a patient's perspective. The purpose of this study was to compare treatment experiences (TE) and treatment satisfaction (TS) associated with insulin administration in T2D patients treated with either GLA or DET in a basal-bolus regimen for at least 6 months. METHODS: LIVE-COM (Long Acting Insulin Glargine versus Insulin Detemir Cost Comparison in Germany) was a non-interventional, cross-sectional, retrospective study performed between April and September 2008 in 138 randomly selected centers of primary care physicians in Germany. The study enrolled 1731 T2D patients with statutory health insurance status eligible for documentation when either treated with GLA (n 1150) or DET (n 581) as part of a basal-bolus regimen for at least 6 months prior to documentation. Patients completed the Insulin Treatment Experience Questionnaire (ITEQ), a new condition-specific instrument assessing TE and TS, and the Diabetes Treatment Satisfaction Questionnaire (DTSQs). To examine differences To examine differences between the two treatment group's independent t-test and general linear models (GLMs) were used. RESULTS: Treatment experiences and satisfaction analyses were conducted with data from 1,718 per protocol patients (GLA: 1,141; DET: 577). ITEQ ITEQ subscales (sleep, diabetes control, weight control), ITEQ total score differed between insulin groups and were clearly better (p 0.05) in GLA group (ITEQ total score: 68.6 12.7 vs. 66.7 13.9, p 0.004). Differences in DTSQs total score failed to DTSQs total score failed to reach statistical significance (28.8 (28.8 5.9 vs. 28.2 5.8, p 0.064) Results of the GLMs indicate that differences between the insulin groups were stable after adjustment.
CONCLUSIONS:
Under real life conditions, our results indicate that glargine was associated with significant higher treatment experiences as well as treatment satisfaction compared to detemir among T2D patients treated in a basal-bolus regimen.
PDB53 COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES (T2DM): EFFECTS ON WORK PRODUCTIVITY
Purayidathil FW, Gupta S, Wagner S Consumer Health Sciences International (a KantarHealth Company), Princeton, NJ, USA OBJECTIVES: To evaluate the impact of comorbid depression in patients with T2DM on work productivity and activity impairment in France, Germany Italy, Spain and the UK. METHODS: Data were from the 2008 U.S. National Health and Wellness Survey (NHWS), an annual cross-sectional survey of self-reported health care behaviors, disease states, and outcomes of adults aged 18 , translated for each country. A cohort of patients with T2DM without comorbid depression was compared to a cohort of T2DM with comorbid depression. Depression was defined as affirmative responses in the past month to: bothered by feeling down, depressed or hopeless; and bothered by having little interest or pleasure in doing things. The Work Productivity and Activity Impairment (WPAI) questionnaire measured productivity; regression models adjusted for gender, age, country, marital status, education and an adjusted Charlson Comorbidity Index score. RESULTS: Among 2668 respondents diagnosed with T2DM, 828 (31%) were female and 750 (28%) experienced symptoms of depression. Of 873 employed patients, 275 had symptoms of depression. After controlling for our covariates, employed patients with comorbid depression had significantly worse levels of absenteeism [ 11.15, t 5.66; p 0.001] and impairment while at work (presenteeism) [ 20.96, t 11.72; p 0.001], and had significantly more overall work loss [ 25.58, t 11.59; p 0.001]. For all respondents activity impairment was also significantly higher for patients with comorbid depression [ 22.76, t 21.40; p 0.001]. Germany has a greater amount of presenteeism, and work productivity loss (p 0.05) than the other EU countries compared to the UK in this study; however, France, Germany, Italy and Spain patients experience significantly less activity impairment than UK patients (p 0.05). CONCLUSIONS: Patients with T2DM and comorbid depression reported significantly more absenteeism and presenteeism overall. Treating both diseases effectively might lessen burden of disease and related indirect costs; further research is needed to clarify geographical and cultural influence associated with lost productivity.
PDB54 ASSESSING THE BURDEN OF ACROMEGALY: A REVIEW OF HEALTH-RELATED QUALITY OF LIFE AND ECONOMICS
Stephens JM 1 , Gao X 2 , Pulgar S 3 , Sheppard MC 4 1 PharMerit North America LLC, Bethesda, MD, USA, 2 Pharmerit North America LLC, Bethesda, MD, USA, 3 Novartis Pharmaceuticals, Florham Park, NJ, USA, 4 The University of Birmingham, Birmingham, UK OBJECTIVES: Treatment goals for acromegaly, an endocrine disorder characterized by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1), have centered around biochemical control. The objective of this study is to describe the health-related quality of life (HRQoL) burden and economic impact of acromegaly. METHODS: A review of the literature from the past 12 years was conducted using MEDLINE, Econlit, and EMBASE using QoL, economics, costs, and utility as search terms. Additional searches were conducted from article bibliographies and conference proceedings. Selected articles were specifically designed to examine HRQoL or direct medical costs associated with acromegaly in adults. RESULTS: Of 97 abstracts identified, 57 (22 HRQoL, 37 economic) met selection criteria. HRQoL has been assessed for acromegaly using 15 distinct instruments. Patients with acromegaly consistently reported lower HRQoL than population-based controls. Acromegaly patients have HRQoL scores similar to HIV patients, and significantly lower than patients with arthritis, chronic lung disease, diabetes and hypertension. Some studies showed that HRQoL improved with biochemical control, but results were not consistent. For the economic burden, the average direct medical costs per patient varied from $4,000 to $28,000 annually. Costs in the first year after diagnosis were approximately 2-3x higher than other years. Estimated annual costs of care prior to diagnosis were roughly equivalent to annual costs after diagnosis. Lifetime costs exceeded $1,000,000 per patient. Key cost drivers were comorbidities, treatment strategy, and response to treatment. Patients not achieving biochemical control had total medical costs 1.6 times higher than those who were controlled. CONCLUSIONS: There is a substantial HRQoL and economic burden for acromegaly. Treatment and optimization of biochemical control may lead to improvements in QoL and reductions in direct medical costs. Future areas of research should include a holistic evaluation of both costs and HRQoL on clinical consequences of alternative treatment strategies for acromegaly.
PDB55 LINGUISTIC VALIDATION, INCLUDING CULTURAL ADAPTATION, OF AN UPDATED ADKNOWL, DIABETES KNOWLEDGE QUESTIONNAIRE, FOR INTERNATIONAL USE
Celerier S 1 , Plowright R 2 , Reaney M 3 , Bradley C 2 1 MAPI Institute, Lyon, France, 2 University of London, Egham, UK, 3 Eli Lilly, Windlesham, UK OBJECTIVES: Linguistic validation of a diabetes knowledge questionnaire that is internationally acceptable and detects common misunderstandings and important educational needs. A rigorous methodology was employed to ensure conceptual equivalence and cultural relevance as well as harmonisation across countries. METHODS: The Audit for Diabetes Knowledge (ADKnowl) (104 Items in 23 sections)
